NOVOLIN 70/30 Drug Profile
✉ Email this page to a colleague
Summary for Tradename: NOVOLIN 70/30
| High Confidence Patents: | 2 |
| Applicants: | 1 |
| BLAs: | 1 |
| Recent Clinical Trials: | See clinical trials for NOVOLIN 70/30 |
Recent Clinical Trials for NOVOLIN 70/30
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| University of Illinois at Chicago | Phase 2 |
| State University of New York - Downstate Medical Center | Phase 4 |
| University of California, San Francisco | N/A |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- General brand-side disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for NOVOLIN 70/30 Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for NOVOLIN 70/30 Derived from Company Disclosures
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc. | NOVOLIN 70/30 | insulin isophane human and insulin human | Injection | 019991 | ⤷ Try a Trial | 2008-02-10 | Company disclosures |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
3) Low Certainty: US Patents for NOVOLIN 70/30 Derived from Patent Text Search
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Patent No. | Estimated Patent Expiration | Source |
|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc. | NOVOLIN 70/30 | insulin isophane human and insulin human | Injection | 019991 | ⤷ Try a Trial | 2033-03-11 | Patent claims search |
| Novo Nordisk Inc. | NOVOLIN 70/30 | insulin isophane human and insulin human | Injection | 019991 | ⤷ Try a Trial | 2029-05-13 | Patent claims search |
| Novo Nordisk Inc. | NOVOLIN 70/30 | insulin isophane human and insulin human | Injection | 019991 | ⤷ Try a Trial | 2036-02-19 | Patent claims search |
| Novo Nordisk Inc. | NOVOLIN 70/30 | insulin isophane human and insulin human | Injection | 019991 | ⤷ Try a Trial | 2033-03-11 | Patent claims search |
| Novo Nordisk Inc. | NOVOLIN 70/30 | insulin isophane human and insulin human | Injection | 019991 | ⤷ Try a Trial | 2029-05-13 | Patent claims search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Patent No. | >Estimated Patent Expiration | >Source |
International Patents for NOVOLIN 70/30
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 3066689 | ⤷ Try a Trial |
| South Korea | 900700149 | ⤷ Try a Trial |
| China | 1035055 | ⤷ Try a Trial |
| Germany | 68901190 | ⤷ Try a Trial |
| South Africa | 89902 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
